PCART-3

N/A

Report date: 2025/01/26 16:46:29

Base Information

Drug NamePCART-3
Drug Alias NameAnti-CD3epsilon CAR T-cell therapy (MediSix Therapeutics/National University of Singapore)anti-CD3 PEBL-CAR T-cellsPCART-3
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT cell surface glycoprotein CD3 modulators
TargetsT cell surface glycoprotein CD3
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySingapore
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesNational University Of Singapore
China Registration ClassN/A

Develop Information

Active CompaniesMediSix TherapeuticsNational University Of Singapore
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, T-Cell, Cutaneous
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A